These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 10867848

  • 1. Enalapril in paediatric patients with Alport syndrome: 2 years' experience.
    Proesmans W, Knockaert H, Trouet D.
    Eur J Pediatr; 2000 Jun; 159(6):430-3. PubMed ID: 10867848
    [Abstract] [Full Text] [Related]

  • 2. Enalapril in children with Alport syndrome.
    Proesmans W, Van Dyck M.
    Pediatr Nephrol; 2004 Mar; 19(3):271-5. PubMed ID: 14745635
    [Abstract] [Full Text] [Related]

  • 3. Angiotensin converting enzyme inhibitor therapy in children with Alport syndrome: effect on urinary albumin, TGF-beta, and nitrite excretion.
    Adler L, Mathew R, Futterweit S, Frank R, Gauthier BG, Kashtan CE, Trachtman H.
    BMC Nephrol; 2002 Feb 14; 3():2. PubMed ID: 11869456
    [Abstract] [Full Text] [Related]

  • 4. Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome.
    Webb NJ, Shahinfar S, Wells TG, Massaad R, Gleim GW, McCrary Sisk C, Lam C.
    Pediatr Nephrol; 2013 May 14; 28(5):737-43. PubMed ID: 23207876
    [Abstract] [Full Text] [Related]

  • 5. Enalapril: antiproteinuric effect in children with nephrotic syndrome.
    Lama G, Luongo I, Piscitelli A, Salsano ME.
    Clin Nephrol; 2000 Jun 14; 53(6):432-6. PubMed ID: 10879662
    [Abstract] [Full Text] [Related]

  • 6. Long-term therapy with enalapril in patients with nephrotic-range proteinuria.
    Proesmans W, Wambeke IV, Dyck MV.
    Pediatr Nephrol; 1996 Oct 14; 10(5):587-9. PubMed ID: 8897561
    [Abstract] [Full Text] [Related]

  • 7. Enalapril and prednisone in children with nephrotic-range proteinuria.
    Delucchi A, Cano F, Rodriguez E, Wolff E, Gonzalez X, Cumsille MA.
    Pediatr Nephrol; 2000 Oct 14; 14(12):1088-91. PubMed ID: 11045392
    [Abstract] [Full Text] [Related]

  • 8. ACE inhibitorenalapril diminishes albuminuria in patients with cystinosis.
    Levtchenko E, Blom H, Wilmer M, van den Heuvel L, Monnens L.
    Clin Nephrol; 2003 Dec 14; 60(6):386-9. PubMed ID: 14690254
    [Abstract] [Full Text] [Related]

  • 9. Alport syndrome: the effects of spironolactone on proteinuria and urinary TGF-β1.
    Giani M, Mastrangelo A, Villa R, Turolo S, Marra G, Tirelli AS, Hopfer H, Edefonti A.
    Pediatr Nephrol; 2013 Sep 14; 28(9):1837-42. PubMed ID: 23748277
    [Abstract] [Full Text] [Related]

  • 10. Losartan and enalapril are comparable in reducing proteinuria in children.
    Webb NJ, Shahinfar S, Wells TG, Massaad R, Gleim GW, Santoro EP, Sisk CM, Lam C.
    Kidney Int; 2012 Oct 14; 82(7):819-26. PubMed ID: 22739977
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of enalapril in the treatment of steroid resistant idiopathic nephrotic syndrome.
    Prasher PK, Varma PP, Baliga KV.
    J Assoc Physicians India; 1999 Feb 14; 47(2):180-2. PubMed ID: 10999084
    [Abstract] [Full Text] [Related]

  • 12. Angiotensin-converting enzyme inhibition ameliorates the defect in glomerular size selectivity in hyponatremic hypertensive syndrome.
    Remuzzi A, Schieppati A, Battaglia C, Remuzzi G.
    Am J Kidney Dis; 1989 Sep 14; 14(3):170-7. PubMed ID: 2476029
    [Abstract] [Full Text] [Related]

  • 13. Long-term treatment by ACE inhibitors and angiotensin receptor blockers in children with Alport syndrome.
    Zhang Y, Wang F, Ding J, Zhang H, Liu X, Wang S, Xiao H, Yao Y, Liu J, Zhong X, Guan N, Su B, Wu G, Yu L.
    Pediatr Nephrol; 2016 Jan 14; 31(1):67-72. PubMed ID: 26248473
    [Abstract] [Full Text] [Related]

  • 14. Enalapril dosage in progressive chronic nephropathy: a randomised, controlled trial.
    Elung-Jensen T, Heisterberg J, Sonne J, Strandgaard S, Kamper AL.
    Eur J Clin Pharmacol; 2005 Apr 14; 61(2):87-96. PubMed ID: 15761754
    [Abstract] [Full Text] [Related]

  • 15. Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease.
    Ecder T, Edelstein CL, Chapman AB, Johnson AM, Tison L, Gill EA, Brosnahan GM, Schrier RW.
    Nephrol Dial Transplant; 1999 May 14; 14(5):1113-6. PubMed ID: 10344347
    [Abstract] [Full Text] [Related]

  • 16. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
    Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J, Diabetics Exposed to Telmisartan and Enalapril Study Group.
    N Engl J Med; 2004 Nov 04; 351(19):1952-61. PubMed ID: 15516696
    [Abstract] [Full Text] [Related]

  • 17. Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease.
    Nakamura T, Fujiwara N, Kawagoe Y, Sugaya T, Ueda Y, Koide H.
    Eur J Clin Invest; 2010 Sep 04; 40(9):790-6. PubMed ID: 20584070
    [Abstract] [Full Text] [Related]

  • 18. Treatment of X-linked hereditary nephritis in Samoyed dogs with angiotensin converting enzyme (ACE) inhibitor.
    Grodecki KM, Gains MJ, Baumal R, Osmond DH, Cotter B, Valli VE, Jacobs RM.
    J Comp Pathol; 1997 Oct 04; 117(3):209-25. PubMed ID: 9447482
    [Abstract] [Full Text] [Related]

  • 19. Renoprotection by ACE inhibitors after severe hemolytic uremic syndrome.
    Van Dyck M, Proesmans W.
    Pediatr Nephrol; 2004 Jun 04; 19(6):688-90. PubMed ID: 15064939
    [Abstract] [Full Text] [Related]

  • 20. Nitrendipine and enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes.
    Mosconi L, Ruggenenti P, Perna A, Mecca G, Remuzzi G.
    Kidney Int Suppl; 1996 Jun 04; 55():S91-3. PubMed ID: 8743521
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.